PMID- 37096236
OWN - NLM
STAT- MEDLINE
DCOM- 20230426
LR  - 20230426
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2023
DP  - 2023
TI  - Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star 
      in Type 2 Diabetes.
PG  - 5891532
LID - 10.1155/2023/5891532 [doi]
LID - 5891532
AB  - Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that 
      has become a growing health problem worldwide, and the dangers of hyperglycemia 
      and its chronic complications have long been considered a goal of diabetes 
      treatment. In recent years, tirzepatide has become the first dual GIP/GLP-1R 
      agonist approved for the treatment of diabetes mellitus in the United States as a 
      new hypoglycemic medicine. Its hypoglycaemic and weight loss effects have been 
      demonstrated in several large clinical trials, and there is also evidence that it 
      has great potential for cardiovascular protection. In addition, the very concept 
      of synthetic peptides opens up many unknown possibilities for tirzepatide. 
      Ongoing trials (NCT04166773) and evidence suggest that it appears to be a 
      promising drug in the areas of NAFLD, renal, and neuroprotection. Based on 
      preclinical studies and clinical trials, the aim of this article is to discuss 
      the latest clinical developments in tirzepatide, to focus on its differences with 
      other incretin therapies, and to suggest future possibilities and mechanisms of 
      tirzepatide therapy.
CI  - Copyright (c) 2023 Zijun Ma et al.
FAU - Ma, Zijun
AU  - Ma Z
AUID- ORCID: 0009-0007-1327-435X
AD  - Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Daling Road 
      16, Shiyan, Hubei 442000, China.
FAU - Jin, Kaiqin
AU  - Jin K
AUID- ORCID: 0009-0007-2119-5846
AD  - Department of Cardiology, The Second Hospital of Anhui Medical University, Furong 
      Road 678, Hefei, Anhui 230601, China.
FAU - Yue, Mengmeng
AU  - Yue M
AUID- ORCID: 0009-0007-5665-2998
AD  - Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Daling Road 
      16, Shiyan, Hubei 442000, China.
FAU - Chen, Xin
AU  - Chen X
AUID- ORCID: 0000-0001-8220-1575
AD  - Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Daling Road 
      16, Shiyan, Hubei 442000, China.
FAU - Chen, Jun
AU  - Chen J
AUID- ORCID: 0000-0002-9071-2436
AD  - Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Daling Road 
      16, Shiyan, Hubei 442000, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230415
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - OYN3CCI6QE (tirzepatide)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Gastric Inhibitory Polypeptide
MH  - Hypoglycemic Agents
PMC - PMC10122586
COIS- The authors declare that there is no conflict of interest.
EDAT- 2023/04/25 06:42
MHDA- 2023/04/26 06:42
PMCR- 2023/04/15
CRDT- 2023/04/25 02:12
PHST- 2023/02/08 00:00 [received]
PHST- 2023/03/23 00:00 [revised]
PHST- 2023/03/27 00:00 [accepted]
PHST- 2023/04/26 06:42 [medline]
PHST- 2023/04/25 06:42 [pubmed]
PHST- 2023/04/25 02:12 [entrez]
PHST- 2023/04/15 00:00 [pmc-release]
AID - 10.1155/2023/5891532 [doi]
PST - epublish
SO  - J Diabetes Res. 2023 Apr 15;2023:5891532. doi: 10.1155/2023/5891532. eCollection 
      2023.